HCAT
$1.23+0.01 (+1.23%)
Health Catalyst, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments, Technology and Professional Services. It offers ignite data and analytics platform that ...
Recent News
Health Catalyst, Inc. (HCAT) Cut to Equal Weight at Wells Fargo on Prolonged Revenue, Margin Pressure
Health Catalyst, Inc. (NASDAQ:HCAT) is one of the best Robinhood stocks on this list. TheFly reported on March 18 that Wells Fargo lowered its rating on HCAT to Equal Weight from Overweight and slashed its price target from $5 to $1. According to the firm, recent sales and strategic adjustments are unlikely to boost performance […]
3 Value Stocks with Questionable Fundamentals
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Health Catalyst (HCAT) Stock Trades Down, Here Is Why
Shares of healthcare data analytics company Health Catalyst (NASDAQ:HCAT) fell 4.2% in the afternoon session after Wells Fargo downgraded the company's stock to Equal Weight from Overweight and significantly cut its price target.
1 Russell 2000 Stock on Our Buy List and 2 That Underwhelm
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
HCAT Q4 Deep Dive: Margin Focus and Strategic Review Amid Platform Migration Pressures
Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 6.2% year on year to $74.68 million. On the other hand, next quarter’s revenue guidance of $69 million was less impressive, coming in 7.9% below analysts’ estimates. Its non-GAAP profit of $0.08 per share was 16.1% below analysts’ consensus estimates.